Published in
American Association for the Advancement of Science, Science Translational Medicine, 511(11), 2019
DOI: 10.1126/scitranslmed.aaw9414
Links
Tools
CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies
Journal article published in 2019 by
Hong Qin 
,
Zhenyuan Dong ,
Xiuli Wang ,
Wesley A. Cheng,
Feng Wen ,
Weili Xue ,
Han Sun,
Miriam Walter ,
Guowei Wei,
D. Lynne Smith,
Xiuhua Sun,
Fan Fei ,
Jianming Xie ,
Theano I. Panagopoulou ,
Chun-Wei Chen
and other authors.
,
Zhenyuan Dong ,
Xiuli Wang ,
Wesley A. Cheng,
Feng Wen ,
Weili Xue ,
Han Sun,
Miriam Walter ,
Guowei Wei,
D. Lynne Smith,
Xiuhua Sun,
Fan Fei ,
Jianming Xie ,
Theano I. Panagopoulou ,
Chun-Wei Chen
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
BAFF receptor is a target for CAR T cell therapy of B cell malignancies, circumventing issues with CD19 antigen loss in tumors.